Drugs / Intestinal Microbiota Transplant
Intestinal Microbiota Transplant
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04884971 | Nov 2021 → Dec 2023 | pulmonary arterial hypertension | University of Minnesota | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05548452 | Nov 2022 → May 2027 expected | alcoholic liver disease, cirrhosis of liver | Virginia Commonwealth University | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intestinal Microbiota Transplant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05548452 ↗ |
| Known as | IMT | “Intestinal Microbiota Transplant (IMT) Capsules” NCT05548452 ↗1“Intestinal microbiota transplant (IMT)” NCT04884971 ↗ |
| Known as | microbiota transplant therapy | “Here, we show that microbiota transplant therapy (MTT) is safe and feasible.” PMID 40803054 ↗ Aug 2025 |
| Known as | MTT | “Here, we show that microbiota transplant therapy (MTT) is safe and feasible.” PMID 40803054 ↗ Aug 2025 |
| Modality | Other / unclassified | “Active drug in capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors” NCT04884971 ↗ |
| Route | Oral | “Two size 00 capsules from a single lot will be taken daily.” NCT04884971 ↗ |